The U.S. Court of Appeals for the Federal Circuit upheld a lower-court ruling that allows Teva Pharmaceutical Industries to sell its generic version of Protonix, a heartburn drug by Wyeth and Altana. A Wyeth spokesman said the company continues to believe in the strength of its patent for Protonix despite the decision.
Patients with nonalcoholic fatty liver disease are three times more likely to develop diabetes and are at a higher risk for metabolic syndrome than those who do not have NAFLD, according to new research. Study authors suggest that the link may be due to common risk factors such as obesity and hyperglycemia.
A new study found obese adults who have high blood pressure and coronary artery disease have a lower risk of heart attack, stroke or death compared to people of normal weight. Researchers are not certain what causes this "obesity paradox" and still encourage weight reduction for heart disease patients.
Older patients with high blood pressure are less likely to receive guidance on how to lower their blood pressure with lifestyle changes than younger patients, according to a study. Researchers also found patients who are not overweight are less likely to receive lifestyle advice than younger patients, compared to those who are overweight.
Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd. have obtained 180-day exclusive rights to sell a generic version of Protonix, a heartburn and anti-ulcer treatment. However, a pending patent infringement suit filed by Wyeth and Altana Pharma AG in New Jersey District Court against Sun and Teva likely will deter them from immediately launching the product.